Logo image of EVLO

EVELO BIOSCIENCES INC (EVLO) Stock Fundamental Analysis

NASDAQ:EVLO - Nasdaq - US2997342025 - Common Stock - Currency: USD

0.3165  -0.05 (-14.46%)

After market: 0.3159 0 (-0.19%)

Fundamental Rating

0

Taking everything into account, EVLO scores 0 out of 10 in our fundamental rating. EVLO was compared to 553 industry peers in the Biotechnology industry. EVLO may be in some trouble as it scores bad on both profitability and health. EVLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVLO has reported negative net income.
In the past year EVLO has reported a negative cash flow from operations.
EVLO had negative earnings in each of the past 5 years.
EVLO had a negative operating cash flow in each of the past 5 years.
EVLO Yearly Net Income VS EBIT VS OCF VS FCFEVLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -399.71%, EVLO is not doing good in the industry: 97.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROIC N/A
ROA(3y)-140.08%
ROA(5y)-110.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVLO Yearly ROA, ROE, ROICEVLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K

1.3 Margins

EVLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVLO Yearly Profit, Operating, Gross MarginsEVLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for EVLO has been increased compared to 1 year ago.
Compared to 1 year ago, EVLO has a worse debt to assets ratio.
EVLO Yearly Shares OutstandingEVLO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
EVLO Yearly Total Debt VS Total AssetsEVLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

EVLO has an Altman-Z score of -53.01. This is a bad value and indicates that EVLO is not financially healthy and even has some risk of bankruptcy.
EVLO's Altman-Z score of -53.01 is on the low side compared to the rest of the industry. EVLO is outperformed by 97.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.01
ROIC/WACCN/A
WACCN/A
EVLO Yearly LT Debt VS Equity VS FCFEVLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

EVLO has a Current Ratio of 0.47. This is a bad value and indicates that EVLO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.47, EVLO is not doing good in the industry: 95.02% of the companies in the same industry are doing better.
EVLO has a Quick Ratio of 0.47. This is a bad value and indicates that EVLO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.47, EVLO is doing worse than 94.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47
EVLO Yearly Current Assets VS Current LiabilitesEVLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

EVLO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -131.81%.
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EVLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.98% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.07%
EPS Next 2Y38.62%
EPS Next 3Y24.47%
EPS Next 5Y14.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EVLO Yearly Revenue VS EstimatesEVLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 20M 40M 60M 80M 100M
EVLO Yearly EPS VS EstimatesEVLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVLO. In the last year negative earnings were reported.
Also next year EVLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVLO Price Earnings VS Forward Price EarningsEVLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVLO Per share dataEVLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20 -25

4.3 Compensation for Growth

A more expensive valuation may be justified as EVLO's earnings are expected to grow with 24.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVLO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVELO BIOSCIENCES INC

NASDAQ:EVLO (12/11/2023, 8:00:02 PM)

After market: 0.3159 0 (-0.19%)

0.3165

-0.05 (-14.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/bmo
Earnings (Next)03-14 2024-03-14/amc
Inst Owners0.14%
Inst Owner Change0%
Ins Owners17.39%
Ins Owner Change0%
Market Cap5.99M
Analysts45.71
Price Target10.2 (3122.75%)
Short Float %0.04%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.9%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-29
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.89
OCFYN/A
SpS0
BVpS-1.41
TBVpS-1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-140.08%
ROA(5y)-110.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z -53.01
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.53%
Cap/Depr(5y)123.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
EPS Next Y85.07%
EPS Next 2Y38.62%
EPS Next 3Y24.47%
EPS Next 5Y14.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.33%
EBIT Next 3Y7.12%
EBIT Next 5YN/A
FCF growth 1Y17.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.09%
OCF growth 3YN/A
OCF growth 5YN/A